
    
      The total duration of the study period per participants was 46 weeks comprising 3 periods:

        -  a 4-week screening period,

        -  a 36-week double-blind treatment period,

        -  a 6-week post-treatment follow-up period.

      Participants who successfully completed the double-blind treatment phase were offered the
      possibility to continue study treatment in the extension study LTS6048 - NCT00228163.
    
  